Target intelligence / Profile preview

novel transcript, antisense to dynein axonemal heavy chain 14 (ENSG00000298651)

Target
ENSG00000298651
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other
01

Overview

This is a novel, natural antisense transcript (NAT) identified as an RNA sequence transcribed from the genomic region antisense to the dynein axonemal heavy chain 14 (DNAH14) gene[1][6]. Such antisense transcripts are typically classified as long non-coding RNAs (lncRNAs); they often do not encode proteins, but may be involved in regulating gene expression of the sense transcript (here, DNAH14) through mechanisms such as RNA interference, chromatin remodeling, or modulation of mRNA stability[6][8]. No direct evidence supports a specific biological function, disease association, or therapeutic potential for this transcript, and it is not currently considered a druggable gene product. The entry is correctly annotated in genomic resources as an uncharacterized antisense lncRNA, and substantial functional or structural characterization is lacking. If you require structured extraction or mapping to other databases, note that almost all known information is at the annotation level, rather than functional or therapeutic (i.e., it is not a characterized "receptor, enzyme, or similar protein-coding gene")[1][6][8].

Other names
LOC105373109novel transcript, antisense to DNAH14ENSG00000298651
02

Biological functions

Gene expression regulation (potential, by antisense mechanism)Other (Antisense transcripts may affect chromatin structure, RNA stability, and transcription of the sense gene, but specific experimental data for this transcript is lacking)
03

Disease associations

Other (No established disease associations for this specific transcript. Antisense lncRNAs in general may play roles in human disease, but this has not been established here)

Beyond the preview

Go deeper on novel transcript, antisense to dynein axonemal heavy chain 14 (ENSG00000298651).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel transcript, antisense to dynein axonemal heavy chain 14 (ENSG00000298651).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call